AIM
Price
$0.20
Change
-$0.01 (-4.76%)
Updated
Dec 18, 04:54 PM (EDT)
110 days until earnings call
PIRS
Price
$13.60
Change
-$2.53 (-15.69%)
Updated
Dec 13 closing price
Ad is loading...

AIM vs PIRS

Header iconAIM vs PIRS Comparison
Open Charts AIM vs PIRSBanner chart's image
AIM ImmunoTech
Price$0.20
Change-$0.01 (-4.76%)
Volume$440
CapitalizationN/A
Pieris Pharmaceuticals
Price$13.60
Change-$2.53 (-15.69%)
Volume$51.73K
CapitalizationN/A
AIM vs PIRS Comparison Chart
Loading...
AIM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PIRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AIM vs. PIRS commentary
Dec 19, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AIM is a Hold and PIRS is a Hold.

COMPARISON
Comparison
Dec 19, 2024
Stock price -- (AIM: $0.21 vs. PIRS: $13.60)
Brand notoriety: AIM and PIRS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AIM: 95% vs. PIRS: 191%
Market capitalization -- AIM: $13.43M vs. PIRS: $17.96M
AIM [@Biotechnology] is valued at $13.43M. PIRS’s [@Biotechnology] market capitalization is $17.96M. The market cap for tickers in the [@Biotechnology] industry ranges from $486.73B to $0. The average market capitalization across the [@Biotechnology] industry is $2.68B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AIM’s FA Score shows that 0 FA rating(s) are green whilePIRS’s FA Score has 1 green FA rating(s).

  • AIM’s FA Score: 0 green, 5 red.
  • PIRS’s FA Score: 1 green, 4 red.
According to our system of comparison, PIRS is a better buy in the long-term than AIM.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AIM’s TA Score shows that 6 TA indicator(s) are bullish while PIRS’s TA Score has 4 bullish TA indicator(s).

  • AIM’s TA Score: 6 bullish, 2 bearish.
  • PIRS’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, AIM is a better buy in the short-term than PIRS.

Price Growth

AIM (@Biotechnology) experienced а -3.44% price change this week, while PIRS (@Biotechnology) price change was -20.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -6.67%. For the same industry, the average monthly price growth was -1.91%, and the average quarterly price growth was -1.42%.

Reported Earning Dates

AIM is expected to report earnings on Apr 07, 2025.

PIRS is expected to report earnings on Aug 01, 2024.

Industries' Descriptions

@Biotechnology (-6.67% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PIRS($18M) has a higher market cap than AIM($13.4M). PIRS YTD gains are higher at: -6.593 vs. AIM (-52.148). PIRS has less debt than AIM: PIRS (0) vs AIM (3.35M).
AIMPIRSAIM / PIRS
Capitalization13.4M18M74%
EBITDAN/AN/A-
Gain YTD-52.148-6.593791%
P/E RatioN/AN/A-
RevenueN/AN/A-
Total CashN/A89.9M-
Total Debt3.35M0-
FUNDAMENTALS RATINGS
AIM vs PIRS: Fundamental Ratings
AIM
PIRS
OUTLOOK RATING
1..100
886
VALUATION
overvalued / fair valued / undervalued
1..100
57
Fair valued
24
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9898
PRICE GROWTH RATING
1..100
8958
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
8550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PIRS's Valuation (24) in the Biotechnology industry is somewhat better than the same rating for AIM (57) in the null industry. This means that PIRS’s stock grew somewhat faster than AIM’s over the last 12 months.

PIRS's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as AIM (100) in the null industry. This means that PIRS’s stock grew similarly to AIM’s over the last 12 months.

PIRS's SMR Rating (98) in the Biotechnology industry is in the same range as AIM (98) in the null industry. This means that PIRS’s stock grew similarly to AIM’s over the last 12 months.

PIRS's Price Growth Rating (58) in the Biotechnology industry is in the same range as AIM (89) in the null industry. This means that PIRS’s stock grew similarly to AIM’s over the last 12 months.

PIRS's P/E Growth Rating (100) in the Biotechnology industry is in the same range as AIM (100) in the null industry. This means that PIRS’s stock grew similarly to AIM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AIMPIRS
RSI
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 6 days ago
73%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 6 days ago
77%
Momentum
ODDS (%)
Bullish Trend 2 days ago
77%
Bearish Trend 6 days ago
90%
MACD
ODDS (%)
Bullish Trend 2 days ago
88%
Bearish Trend 6 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 6 days ago
87%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 6 days ago
87%
Advances
ODDS (%)
Bullish Trend 6 days ago
79%
Bullish Trend 9 days ago
83%
Declines
ODDS (%)
Bearish Trend 8 days ago
86%
Bearish Trend 6 days ago
84%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 6 days ago
79%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
View a ticker or compare two or three
Ad is loading...
AIM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PIRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GME31.261.82
+6.18%
GameStop Corp
TSLA479.8616.84
+3.64%
Tesla
AAPL253.482.44
+0.97%
Apple
BTC.X106140.600000110.890625
+0.10%
Bitcoin cryptocurrency
SPY604.29-2.50
-0.41%
SPDR® S&P 500® ETF Trust

AIM and

Correlation & Price change

A.I.dvisor tells us that AIM and SLN have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that AIM and SLN's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AIM
1D Price
Change %
AIM100%
+0.24%
SLN - AIM
28%
Poorly correlated
-3.41%
ELVN - AIM
27%
Poorly correlated
+3.48%
PIRS - AIM
24%
Poorly correlated
N/A
ENTBF - AIM
23%
Poorly correlated
-2.20%
MNPR - AIM
23%
Poorly correlated
+14.91%
More

PIRS and

Correlation & Price change

A.I.dvisor indicates that over the last year, PIRS has been closely correlated with CDTX. These tickers have moved in lockstep 96% of the time. This A.I.-generated data suggests there is a high statistical probability that if PIRS jumps, then CDTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PIRS
1D Price
Change %
PIRS100%
N/A
CDTX - PIRS
96%
Closely correlated
-1.93%
NCNA - PIRS
95%
Closely correlated
+1.19%
NBY - PIRS
95%
Closely correlated
-4.86%
SNPX - PIRS
94%
Closely correlated
-1.99%
RNAC - PIRS
94%
Closely correlated
-2.71%
More